MGUS and its future in the treatment of myeloma

In this video, Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, shares some insights into the future of the field of monoclonal gammopathy of undetermined significance (MGUS) and the treatment of multiple myeloma (MM). Dr Landgren mentions the likelihood that research will move away from measuring disease burden to precision medicine and genomic identification of individuals at risk of developing MM. Dr Landgren then draws focus on the importance of early detection in MM and analyzing the bone marrow as well as the microenvironment and concludes by mentioning the aims of an upcoming study on MGUS. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.